OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO) reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share. OKYO is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares traded on the Nasdaq Capital Market.

According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

News Market Reaction – OKYO

+5.56%

6 alerts

+5.56% Session close to close

+4.3% Peak Tracked

-3.7% Trough Tracked

$79.77M Market Cap

1.2x Rel. Volume

In the Jul 22 session, OKYO gained 5.56%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.3% during that session. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.6% in the session following this news. -5.14% followed OKYO’s July 8 FDA Type D u...

Analysis

The stock moved +5.6% in the session following this news. -5.14% followed OKYO’s July 8 FDA Type D update, while OVID was up 4.78% in the current peer context. A strong response to the CMO purchase would contrast with that history; the active F-3 shelf adds financing risk.

Key Figures

Shares purchased: 20,000 ordinary shares Purchase price: $1.40 per share Trial phase: Phase 3 +1 more

4 metrics

Shares purchased 20,000 ordinary shares Chief Medical Officer open-market purchase

Purchase price $1.40 per share NASDAQ transaction

Trial phase Phase 3 Global pivotal clinical trial planned for the second half of this year

Planned enrollment Approximately 111 patients Global trial evaluating urcosimod for neuropathic corneal pain

Historical Context

5 past events · Latest: Jul 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 20	Annual report update	Positive	-4.2%	Reported stronger funding and plans for the global Phase 3 NEPTUNE trial.
Jul 08	FDA trial update	Positive	-5.1%	FDA feedback supported advancing urcosimod into a global Phase 3 pivotal trial.
Jul 07	Conference participation	Neutral	+8.7%	Company announced executive participation in a virtual ophthalmology symposium.
May 19	Advisory board appointment	Neutral	-0.0%	OKYO appointed ophthalmology expert Marta Sacchetti to its scientific advisory board.
Apr 29	Scientific conference plans	Neutral	-3.8%	Executives announced presentations and participation at upcoming scientific meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical updates were followed by negative 24-hour reactions in the two most recent clinical-trial events.

Key Terms

neuropathic corneal pain, phase 3, single-dose regimen

3 terms

neuropathic corneal pain medical

"therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

phase 3 medical

"initiate a global Phase 3 pivotal clinical trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

single-dose regimen medical

"evaluate a single-dose regimen of urcosimod"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

What insider share purchase did OKYO Pharma (NASDAQ: OKYO) announce on July 22, 2026?

OKYO Pharma announced that Chief Medical Officer Flavio Mantelli purchased 20,000 ordinary shares at $1.40 per share. According to OKYO Pharma, this transaction occurred on Nasdaq and involved the company’s ordinary shares listed on the Nasdaq Capital Market.

How many OKYO Pharma shares did the Chief Medical Officer buy and at what price?

OKYO Pharma’s Chief Medical Officer bought 20,000 ordinary shares at a price of $1.40 per share. According to OKYO Pharma, these shares were purchased on Nasdaq, where the company’s ordinary shares are listed for trading on the Nasdaq Capital Market.

What clinical trial is OKYO Pharma (OKYO) planning for neuropathic corneal pain?

OKYO Pharma plans a global Phase 3 pivotal trial evaluating urcosimod for neuropathic corneal pain. According to OKYO Pharma, the trial is expected in the second half of this year and will enroll about 111 patients on a single-dose regimen of urcosimod.

When will OKYO Pharma start its Phase 3 urcosimod trial and how many patients are planned?

OKYO Pharma plans to initiate the Phase 3 urcosimod trial in the second half of this year, enrolling approximately 111 patients. According to OKYO Pharma, the study will assess a single-dose regimen for treating neuropathic corneal pain (NCP).

What therapeutic areas does OKYO Pharma focus on with ticker OKYO on Nasdaq?

OKYO Pharma focuses on developing therapies for neuropathic corneal pain and anterior segment eye diseases. According to OKYO Pharma, it is a clinical-stage biopharmaceutical company with ordinary shares listed for trading on the Nasdaq Capital Market under the symbol OKYO.

What is urcosimod in OKYO Pharma’s pipeline for neuropathic corneal pain (NCP)?

Urcosimod is OKYO Pharma’s investigational therapy being advanced for neuropathic corneal pain. According to OKYO Pharma, a global Phase 3 pivotal clinical trial is planned, using a single-dose regimen in approximately 111 patients to evaluate urcosimod in NCP.